BRIEF—Primordial Genetics promises new mRNA manufacturing options

US synthetic biology company Primordial Genetics has announced the launch of its proprietary RNA polymerases to advance safe, viable mRNA-based vaccines and therapeutics.

According to Primordial Genetics, its Prima RNApols enable production of mRNAs with higher yields, higher purity of target RNAs and significantly lower double-stranded RNA levels.

Helge Zieler, Primordial Genetics founder and president, said: “Primordial Genetics’ goal is to develop powerful manufacturing technology for enabling mRNA therapeutics and vaccines. We want to make drug candidates viable that were previously too expensive to manufacture. This can significantly impact the treatment and prevention of human diseases.

“The launch of our Prima RNApols represents new mRNA manufacturing options for the pharmaceutical industry and a huge milestone for Primordial Genetics. Primordial’s Prima RNApols are the most efficient RNA polymerases available with an emphasis on long-template applications which are gaining in importance.”